Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0J5CX
|
|||
Former ID |
DCL001011
|
|||
Drug Name |
TAK-637
|
|||
Synonyms |
TAK-637; UNII-QRT7W0TL6X; QRT7W0TL6X; CHEMBL339486; SCHEMBL122948; TAK637; GTPL9329; TAK 637; BDBM50081420; compound (aR,9R)-8b [PMID: 10508446]; 7H-(1,4)Diazocino(2,1-g)(1,7)naphthyridine-6,13-dione, 7-((3,5-bis(trifluoromethyl)phenyl)methyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)-; (Ar,9R)-7-(3,5-bis(trifluoromethyl)benzyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-(1,4)diazocino(2,1-g)(1,7)naphthyridine-6,13-dione
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Discontinued in Phase 2 | [1] | |
Company |
Takeda
|
|||
Structure |
Download2D MOL |
|||
Formula |
C30H25F6N3O2
|
|||
Canonical SMILES |
CC1CCN2C(=C(C3=C(C2=O)N=CC=C3)C4=CC=C(C=C4)C)C(=O)N(C1)CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
|
|||
InChI |
1S/C30H25F6N3O2/c1-17-5-7-20(8-6-17)24-23-4-3-10-37-25(23)27(40)39-11-9-18(2)15-38(28(41)26(24)39)16-19-12-21(29(31,32)33)14-22(13-19)30(34,35)36/h3-8,10,12-14,18H,9,11,15-16H2,1-2H3/t18-/m1/s1
|
|||
InChIKey |
LDXQLWNPGRANTO-GOSISDBHSA-N
|
|||
CAS Number |
CAS 183549-93-1
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Substance-P receptor (TACR1) | Target Info | Antagonist | [1] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Measles | ||||
Panther Pathway | CCKR signaling map ST | |||
Reactome | G alpha (q) signalling events | |||
WikiPathways | SIDS Susceptibility Pathways | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Spinal Cord Injury | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.